The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Affiliation
Spanish Agency of Medicines and Medical Devices (AEMPS), Department of Medicines for Human Use
Country
Spain
Current position
Dr. Yoana Nuevo-Ordóñez is the head of the Innovation office and National Scientific Advice Unit within the Spanish Agency of Medicines and Medical Devices (AEMPS). Dr Yoana is also the Spanish representative of the European Innovation Network (EU-IN), composed by the National Competent Authorities’ Innovation offices plus the Innovation Task Force (ITF) from EMA. She also leads the theme “Regulatory Science, Innovation and Competitiveness” of the European Medicines Agencies Network Strategy (EMANS) for 2028 and the INNO Group (composed by the EU-IN, SAWP, CTCG and HTA) together with Maria Jesus Lamas (AEMPS Executive Director).
Education
Dr. Yoana Nuevo-Ordóñez studied Chemistry at the University of Oviedo, Spain obtaining her degree in 2005. In 2011 she obtained an European PhD in Analytical Chemistry at the University of Oviedo in collaboration with the University of Aberdeen, Scotland. After doing her post doctorate at the National Institute of Standards and Technology (NIST), USA, she worked 5 years at a Biopharmeceutical company in Spain as head of the quality control department. In 2018 she joined the Spanish Agency (AEMPS) as responsible of the Innovation Office and in 2022 she got a permanent position and was named head of the Innovation Office and National Scientific Advice Unit.
Research area
Dr. Yoana Nuevo-Ordóñez is responsible for the coordination of the AEMPS Innovation Office and National Scientific Advice Unit. She is also in charge of all the activities related with innovation within the Spanish Agency. As a member of the EU-IN is co leading numerous European projects. She leaded together with the EU-IN partners the STARS “Strengthening Training of Academia in Regulatory Science” project funded by the European Commission and now they are implementing the recommendations. She is co leading with the Czech Republic Agency (SUKL) the Horizon Scanning report on nanomedicines, she is co leading together with the Paul Ehrlich institute (PEI) and the federal agency for medicines and health products (FAMHP) in Belgium the Simultaneous National Scientific Advice (SNSA) Pilot and she is also co leading with EMA the European Repurposing project Pilot.
Conflict of interest
None